NDAORALTABLET
Approved
Nov 1962
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 36m ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VALPIN 50 (anisotropine methylbromide) is an oral anticholinergic agent approved in 1962 for gastrointestinal and urinary tract disorders. It functions as a competitive antagonist of acetylcholine at muscarinic receptors, reducing smooth muscle spasm and secretion. This is a legacy small-molecule therapeutic with limited modern clinical use.
LOE Approaching
With LOE approaching and moderate competitive pressure (30), the commercial team is likely focused on cost-containment and retention strategies rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
VALPIN 50 offers limited career growth opportunity; roles focus on portfolio maintenance, compliance, and managed decline. This is a consolidation or legacy product assignment, best suited for professionals seeking stable, lower-intensity commercial operations or those early in their career requiring foundational pharma experience.
Product ManagerRegulatory Affairs Specialist
Worked on VALPIN 50 at Teva? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.